Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 5/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.55 |
| ▸ | XDH | P47989 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CFD | P00746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7193700 | 0.90 | PTPN11 (0.55) | PTPN11PTPN1PTPN6XDHHTT | |
| SCHEMBL4603006 | 0.85 | PTPN11 (0.65) | PTPN11PTPN1PTPN6CFDADRB1 | |
| SCHEMBL7594052 | 0.84 | KDM4E (0.45) | PTPN11PTPN1PTPN6XDHHTT | |
| SCHEMBL9038729 | 0.77 | MAPK1 (0.57) | XDHHTTKDM4EMAPK1 | |
| SCHEMBL7190979 | 0.77 | HTT (0.51) | PTPN11XDHHTTKDM4EMAPK1 | |
| SCHEMBL7184297 | 0.76 | KDM4E (0.44) | PTPN11PTPN1PTPN6XDHHTT | |
| Hydrochloric Acid SCHEMBL9038923 | 0.76 | MAPK1 (0.56) | XDHHTTKDM4EMAPK1 | |
| SCHEMBL4603310 | 0.74 | PTPN11 (0.67) | PTPN11PTPN1PTPN6CFD | |
| SCHEMBL568543 | 0.73 | HTT (0.74) | HTTKDM4EMAPK1 | |
| SCHEMBL29829739 | 0.73 | HTT (0.74) | HTTKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | disclosed |
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | PTPRF, PTPRS, PTPRO | PTPN11 23/4885PTPN1 13/4885PTPN6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.